Issues related to the management and therapy of paediatric pulmonary hypertension

European Respiratory Review

Volumn 19, Issue 118, 2010, Pages 331-339

  Schulze Neick, I ^a   Beghetti, M ^b  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Paediatric; Pulmonary hypertension; Registry; Treatment

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; SILDENAFIL; UNIPROST;

AGE DISTRIBUTION; ARTICLE; CHILD; COMMUNITY CARE; DISEASE CLASSIFICATION; DISEASE REGISTRY; DRUG ADMINISTRATION ROUTE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDICATION; DRUG SPECIFICITY; DRUG TOLERABILITY; GEOGRAPHIC DISTRIBUTION; HEART OUTPUT; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; INCIDENCE; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; PATHOPHYSIOLOGY; PATIENT EDUCATION; POPULATION RESEARCH; PREVALENCE; PULMONARY HYPERTENSION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; WALKING;

ADOLESCENT; AGE FACTORS; ALGORITHMS; ANTIHYPERTENSIVE AGENTS; CHILD; CHILD, PRESCHOOL; HUMANS; HYPERTENSION, PULMONARY; PRACTICE GUIDELINES AS TOPIC; VASODILATOR AGENTS;

EID: 78650364988     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00008510     Document Type: Article

References (41)

1. Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart 2009; 95: 312-317.
2. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
3. Haworth SG. Pulmonary endothelium in the perinatal period. Pharmacol Rep 2006; 58: Suppl., 153-164.
4. Gabbay E, Yeow W, Playford D. Pulmonary arterial hypertension (PAH) is an uncommon cause of pulmonary hypertension (PH) in an unselected population: the Armadale echocardiography study. Am J Resp Crit Care Med 2007; 175: A713.
5. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
6. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137: 376-387.
7. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
8. Launay D, Sitbon O, Le PJ, et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford) 2010; 49: 490-500.
9. Thenappan T, Shah SJ, Rich S, et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010; 35: 1079-1087.
10. Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010; 121: 20-25.
11. Haworth SG, Beghetti M. Assessment of endpoints in the pediatric population: congenital heart disease and idiopathic pulmonary arterial hypertension. Curr Opin Pulm Med 2010; 16: Suppl. 1, S35-S41.
12. van Loon RL, Roofthooft MT, van Osch-Gevers M, et al. Clinical characterization of pediatric pulmonary hypertension: complex presentation and diagnosis. J Pediatr 2009; 155: 176-182.
13. Fasnacht MS, Tolsa JF, Beghetti M. The Swiss registry for pulmonary arterial hypertension: the paediatric experience. Swiss Med Wkly 2007; 137: 510-513.
14. Fraisse A, Jais X, Schleich JM, et al. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Arch Cardiovasc Dis 2010; 103: 66-74.
15. Moledina S, Hislop AA, Foster H, et al. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart 2010; 96: 1401-1406.
16. Konduri GG. New approaches for persistent pulmonary hypertension of newborn. Clin Perinatol 2004; 31: 591-611.
17. Lopes AA, Bandeira AP, Flores PC, et al. Pulmonary hypertension in Latin America: pulmonary vascular disease: the global perspective. Chest 2010; 137: Suppl. 6, 78S-84S.
18. Beghetti M, Berger RMF, Schulze-Neick I, et al. Tracking outcomes and practice in pediatric pulmonary hypertension: the first multinational registry in pediatric pulmonary hypertension. 2008. www.peph-association.org/publications/topp_ers_2008_08_16.pdf
19. Blanc J, Vouhè P, Bonnet D. Potts shunt in patients with pulmonary hypertension. N Engl J Med. 2004; 350: 623.
20. Maiya S, Hislop AA, Flynn Y, et al. Response to bosentan in children with pulmonary hypertension. Heart 2006; 92: 664-670.
21. Beghetti M, Haworth SG, Bonnet D, et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol 2009; 68: 948-955.
22. Tissot C, Beghetti M. Advances in therapies for pediatric pulmonary arterial hypertension. Expert Rev Respir Med 2009; 3: 265-282.
23. Beghetti M, Hoeper MM, Kiely DG, et al. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. Pediatr Res 2008; 64: 200-204.
24. Yung D, Widlitz AC, Rosenzweig EB, et al. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004; 110: 660-665.
25. Nakayama T, Shimada H, Takatsuki S, et al. Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japanese children. Circ J 2007; 71: 1785-1790.
26. Lammers AE, Hislop AA, Flynn Y, et al. Epoprostenol treatment in children with severe pulmonary hypertension. Heart 2007; 93: 739-743.
27. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99: 1197-1208.
28. Ivy DD, Doran AK, Smith KJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51: 161-169.
29. Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000; 84: E4.
30. Oliveira EC, Amaral CF. [Sildenafil in the management of idiopathic pulmonary arterial hypertension in children and adolescents]. J Pediatr (Rio J) 2005; 81: 390-394.
31. Karatza AA, Bush A, Magee AG. Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. Int J Cardiol 2005; 100: 267-273.
32. Humpl T, Reyes JT, Holtby H, et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 2005; 111: 3274-3280.
33. Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003; 73: 372-382.
34. Gilbert N, Luther YC, Miera O, et al. Initial experience with bosentan (tracleer) as treatment for pulmonary arterial hypertension (PAH) due to congenital heart disease in infants and young children. Z Kardiol 2005; 94: 570-574.
35. Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 697-704.
36. Simpson CM, Penny DJ, Cochrane AD, et al. Preliminary experience with bosentan as initial therapy in childhood idio-pathic pulmonary arterial hypertension. J Heart Lung Transplant 2006; 25: 469-473.
37. Lammers AE, Hislop AA, Flynn Y, et al. The six-minute walk test: normal values for children of 4-11 years of age. Arch Dis Child 2008; 93: 464-468.
38. Bernus A, Wagner BD, Accurso F, et al. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest 2009; 135: 745-751.
39. Schulze-Neick I, Beghetti M. Classifying pulmonary hypertension in the setting of the congenitally malformed heart: cleaning up a dog's dinner. Cardiol Young 2008; 18: 22-25.
40. Tissot C, Ivy DD, Beghetti M. Medical therapy for pediatric pulmonary arterial hypertension. J Pediatr. 2010; 157: 528-532.
41. van Loon RL, Hoendermis ES, Duffels MG, et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am Heart J 2007; 154: 776-782.